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Abstract
Background: In central nervous system cholesterol cannot be degraded but is secreted into circulation
predominantly in the form of its polar metabolite 24(S)-hydroxycholesterol (24S-OH-Chol). Some studies suggested
an association between 24S-OH-Chol metabolism and different neurological diseases including dementia. A
possible decrease in 24S-OH-Chol plasma levels has been reported late onset Alzheimer’s disease (LOAD) and
vascular dementia (VD), but results of previous studies are partially contradictory.
Methods: By high-speed liquid chromatography/tandem mass spectrometry we evaluated the plasma levels of
24S-OH-Chol in a sample of 160 older individuals: 60 patients with LOAD, 35 patients with VD, 25 subjects affected
by cognitive impairment no-dementia (CIND), and 40 (144 for genetics study) cognitively normal Controls. We also
investigated the possible association between PPARgamma Pro12Ala polymorphism and dementia or 24S-OH-Chol
levels.
Results: Compared with Controls, plasma 24S-OH-Chol levels were higher in LOAD and lower in VD; a slight not-
significant increase in CIND was observed (ANOVA p: 0.001). A positive correlation between 24S-OH-Chol/TC ratio
and plasma C reactive protein (CRP) levels was found in the whole sample, independent of possible confounders
(multiple regression p: 0.04; r2: 0.10). This correlation was strong in LOAD (r: 0.39), still present in CIND (r: 0.20), but
was absent in VD patients (r: 0.08). The PPARgamma Pro12Ala polymorphism was not associated with the diagnosis
of LOAD, VD, or CIND; no correlation emerged between the Ala allele and 24S-OH-Chol plasma levels.
Conclusions: Our results suggest that plasma 24S-OH-Chol levels might be increased in the first stages of LOAD,
and this phenomenon might be related with systemic inflammation. The finding of lower 24S-OH-Chol
concentrations in VD might be related with a more advanced stage of VD compared with LOAD in our sample,
and/or to different pathogenetic mechanisms and evolution of these two forms of dementia.
Background
Late onset Alzheimer’s disease (LOAD) is the most
common form of dementia in older individuals living in
Western countries, followed by vascular dementia (VD)
[1,2]. Besides a definite role in the pathogenesis of
atherosclerosis, and of consequence of some types of
VD, disturbances of cholesterol homeostasis might have
a role also in the development of LOAD [3,4]. In central
nervous system (CNS) cholesterol originates almost
exclusively from in situ synthesis [5], while circulating
cholesterol is normally prevented from entering the
CNS by the blood-brain-barrier [4]. As cholesterol can-
not be eliminated in CNS, and may be toxic to neurons
when in excess, it is secreted from CNS into the circula-
tion predominantly in the form of its polar metabolite
24(S)-hydroxycholesterol (24S-OH-Chol) [6].
Interestingly, some studies have suggested a possible
association between 24S-OH-Chol metabolism and dif-
ferent neurological diseases [7]. As most of the circulat-
ing 24S-OH-Chol originates in the brain, it has been
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proposed that the concentrations of 24S-OH-Chol in
cerebrospinal fluid and/or plasma might represent per-
ipheral markers of neuronal degeneration occurring in
primary diseases of CNS [8].
It has been reported that 24S-OH-Chol levels were
higher in cerebrospinal fluid from LOAD patients com-
pared to controls [9,10]. On the contrary, 24S-OH-Chol
concentrations were found to be low in brain samples
obtained from deceased patients with LOAD in
advanced stage [11].
Plasma levels of 24S-OH-Chol should reflect the num-
ber of active neurons in the brain and thus, the volume
of the grey matter structures. In different neurodegen-
erative disorders plasma 24S-OH-Chol was found to be
reduced, proportionally to the degree of brain atrophy
as measured by MRI [8]. As regards dementia, only a
few studies conducted on small samples of patients have
investigated this specific topic. At first, slightly higher
24S-OH-Chol levels have been found, both in patients
with LOAD and VD [12]. Subsequent studies gave dif-
ferent results reporting normal [10] or even decreased
24S-OH-Chol levels in patients with LOAD or VD com-
pared with controls [13-15]. Of consequence, findings
about 24S-OH-Chol plasma levels in patients affected by
LOAD and VD are not definite; indeed, it is possible
that brain cholesterol and thus 24S-OH-Chol plasma
levels might change over time along these two neurolo-
gical diseases.
Some studies have also investigated the possible influ-
ence of common DNA polymorphisms on 24S-OH-Chol
plasma levels or the risk of being affected by LOAD. In
particular, the genes coding for the 24S-hydroxylase
(CYP46) and for the peroxisome proliferator-activated
receptor gamma (PPARgamma) have been studied
[16,17].
In the present study we evaluated, by high-speed
liquid chromatography/tandem mass spectrometry, the
plasma levels of 24S-OH-Chol in a sample of older indi-
viduals affected by LOAD, VD, or cognitive impairment
no dementia (CIND); successively, we investigated the
possible association between the PPARgamma Pro12Ala
polymorphism and 24S-OH-Chol levels.
Methods
Subjects
On the whole, 120 consecutive patients referring to the
Day Hospital service for the study of cognitive decline
(Institute of Internal Medicine, Gerontology and Clinical
Nutrition; Geriatric Unit, S. Anna University-Hospital,
Ferrara, Italy) were enrolled. All data were collected
during a three years period (2006-2009). The sample
included:
1) Sixty patients with LOAD (mean age: 78 ± 5.5 SD
years; females: 78%) by the NINCDS-ADRDA criteria
[18]. Only patients with “probable” LOAD were included;
patients with “possible” LOAD or with LOAD associated
with significant cerebrovascular disease on CT scan were
excluded in order to increase specificity. The Global
Deterioration Scale ranged from stage 3 to 5.
2) Thirty five patients with VD (mean age: 77 ± 7.6 SD
years; females: 60%) by the NINDS-AIREN criteria [19].
Only patients with “probable” VD were enrolled. The
Global Deterioration Scale ranged from stage 4 to 6.
3) Twenty five patients with cognitive impairment no
dementia (CIND) (mean age: 74 ± 8.2 SD years; females:
44.5%). CIND was defined as the presence of short/
long-term memory impairment and/or impairment in
other single or multiple cognitive domains in an indivi-
dual who didn’t meet the standardized criteria for
dementia. We also required that the patient with CIND
would be still independent in the activities of daily living
(ADLs). Most of these individuals were affected by
amnesic multi-domain cognitive impairment.
No Cerebrospinal fluid (CSF) biomarkers were avail-
able for all the patients (LOAD, VD, and CIND)
enrolled into this study.
Forty cognitively normal older individuals were
enrolled as controls (C). Their mean age was 72 ± 8.7
SD years; females represented 68% of the sample. All
these individuals were free-living, healthy (no important
comorbidity was found), and were independent on
ADLs (mean Barthel score: 96/100). Their average
MMSE score was 28/30. In case of memory complains,
a battery of tests was administered, as previously
described [20].
For the evaluation of the PPARgamma Pro12Ala poly-
morphisms, additional 104 normal older individuals
were enrolled (mean age: 77 ± 9.1 SD years; females:
52.6%).
Personal data and medical history were collected by a
structured interview from patients and caregivers. All
patients underwent a general and neurological examina-
tion; clinical-chemistry analyses were performed to
exclude causes of secondary cognitive impairment. The
diagnosis of dementia was made by trained geriatricians;
for neuropsychological assessment, all patients were
given a battery of tests [20]. Subjects affected by severe
congestive heart failure (New York Heart Association
class III-IV), severe liver or kidney disease, severe
chronic obstructive pulmonary disease, and cancer were
excluded. There were no evidences of acute illnesses at
the time of clinical observation in DH and blood
sampling.
The criteria for the diagnosis of diabetes were: 1) his-
tory of diabetes or current hypoglycaemic therapy; 2)
fasting glycaemia > 126 mg/dl in two or more measure-
ments; 3) glycaemia > 200 mg/dl at 120 min after oral
glucose load. The criteria for the diagnosis of
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hypertension were: 1) history of hypertension or antihy-
pertensive therapy at visit time; 2) blood pressure >
140/90 mmHg in three or more measurements. The
diagnosis of coronary heart disease (CHD) was made in
the presence of a documented history of previous myo-
cardial infarction or angina. No patients were taking a
statin at the time of enrolment into the study. All sub-
jects (and/or their caregiver if demented) were informed
about the research project during the first visit, and
gave their written consent in order to participate to the
study. The study was approved by the local ethic com-
mittee (S. Anna University Hospital, Ferrara, Italy) and
was conducted in accordance with the Helsinki Declara-
tion as revised in 1989.
Brain CT scan
All patients (LOAD, VD, and CIND) underwent a brain
CT. The instrument used was a third generation SIE-
MENS SOMATON HQ. The slice thickness was 10
mm. Radiograms were evaluated by trained radiologists
not informed about the clinical characteristics of the
patient. CT scan information was used to support the
clinical diagnosis, and to exclude possible brain patholo-
gies associated with cognitive impairment. CT scan was
also used for a qualitative evaluation of brain morphol-
ogy. Brain atrophy was assessed through direct/indirect
signs of neuronal loss. Lacunar infarcts were defined as
demarcated lesions with a diameter < 15 mm involving
deep regions such as internal capsulae, basal ganglia,
corona radiata or thalamus. Cortical infarctions were
defined as the presence of large cortical-subcortical
infarctions resulting from the occlusion of large cerebral
arteries.
Plasma 24S-OH-Chol concentrations measurement
Blood was drown in the morning after a 12-hours over-
night fasting, and after the patient has been sedentary in
sitting or supine position for at least 10 minutes. After
having been aliquoted, plasma was frozen and stored at
-80°C until the tests were performed.
Stock solutions of 24S-OH-Chol and racemic
24OHChol-d6 internal standard (IS), obtained from
Avanti Polar Lipids, were prepared in toluene at a con-
centration of 1 mg/mL. Samples were purified following
a procedure previously described by DeBarber et al.
[21], after adding 5 μL of 5 μg/mL isopropanol IS work-
ing solution, to 500 μL of serum. The dried organic
extract residue was reconstituted in 125 μL of acetoni-
trile/methanol (30/70 v/v). 24S-OH-Chol concentration
was determined using a linear 7-point calibration curve
ranging from 7.85 to 500 ng/mL, prepared evaporating
an aliquot of the 24S-OH-Chol working isopropanol
solutions under flow of pure N2 and redissolving the
dried sample with an appropriate volume of acetonitrile/
methanol (30/70 v/v). 24S-OH-Chol assay was per-
formed using an ultra performance liquid cromatograph
(Dionex Ultimate 3000 RS) coupled with a mass spec-
trometer (AB SCIEX Triple Quadrupole API 3000),
equipped with an atmospheric pressure chemical ioniza-
tion (APCI) source and operating in multiple reaction
monitoring in positive mode. Transition from m/z 385.4
to m/z 367.5 ion was monitored for 24S-OH-Chol and
transition from m/z 391.4 to m/z 373.5 ion for
24OHChol-d6. Chromatographic separation was per-
formed using a Pinnacle DB C18 column (1, 9 um parti-
cle size; 100 × 2.1 mm i.d.; Restek) at a temperature of
50°C, with a mobile phase consisted of MeOH/CH3CN/
H2O 45/45/10+ 0.1% acetic acid (phase A) and CH2Cl/
MeOH (80/20 v/v) (phase B). The eluition gradient was
programmed as follows (flow rate, 0.8 mL/min): 100%
mobile phase A for 5 minute, increased to 100% B in 2
minutes, 5 minutes at 100% B, decreased to 100% A in
1 minute and then reequilibrated with 100% A for 10
minute until the next sample was injected. The linear
regression constant (r) was more than 0.999 in the lin-
ear range 7.85-500 mg/mL. Calibrators accuracy and
interday precision (CV%) ranged respectively from
95.81%-108.5% and 0.6%-11.96%. Recovery was between
102,68% and 95,92%. Intra- and interday precision were
respectively less than 5% and 8% for calculated 24S-OH-
Chol. The detection limit was 1 ng/mL and the quantifi-
cation limit 5 ng/mL. 24S-OH-Chol was reported as
plasma levels (ng/ml).
Plasma cholesterol measurement
Plasma concentrations of total cholesterol (TC) were
measured by standard enzymatic procedures (CHOD-
PAP Method, Boehringer, Mannheim, Germany).
PPARgamma Pro12Ala genotyping
Genomic DNA was extracted from blood leukocytes by
the salting out method. The Pro12Ala PPARgamma var-
iant was detected by polymerase chain reaction-restric-
tion fragment length polymorphism (PCR-RFLP)
analysis. This analysis a mutagenic PCR primer is used
to introduce a BstUI restriction site only when a C®G
substitution at nucleotide 34 of the PPARgamma 2 gene
is present [22]. Genotyping was repeated for all Ala12
homozygotes and Pro12Ala heterozygotes; reproducibil-
ity was 100%.
Statistical analysis
Continuous variables were expressed as mean (SD) or
median (interquartile range) when necessary. The distri-
bution of 24S-OH-Cholesterol values was skewed; con-
sequently, data were expressed as median values
(interquartile range). Means were compared by ANOVA
using the Fisher’s least significant difference (LSD) test
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for post-hoc analysis. 24S-OH-Cholesterol values were
LOG-tranformed before entering ANOVA. Bivariate
correlations were tested by the Pearson’s test. Prevalence
was compared by the c2 test. Multivariate linear regres-
sion analysis (method stepwise forward) was used to test
the association between the 24S-OH-Chol/TC ratio and
other variables previously selected by univariate analysis.
Dicotomous variables were included as dummy variables
(0: absent; 1: present).
SPSS for Windows, version 7.0 (SPSS, Inc, Chicago,
IL)statistical packages were used.
Results
In Table 1 are reported the general characteristics and
the plasma levels of 24S-OH-Chol in patients with
LOAD, VD, CIND, and in C. The prevalence of female
gender was higher in LOAD and lower in VD compared
with the other groups. Mean age was lower, while MMSE
score was higher in C compared with the other groups.
The Barthel index score was higher in C and CIND com-
pared with LOAD and VD. Brain atrophy on CT scan
was more frequently reported in LOAD patients, while
ischemic lesions (both lacunar and cortical infarcts) were
more frequent in VD (Chi square: all p: 0.001).
Compared with C, plasma 24S-OH-Chol levels were
higher in LOAD (LSD post-hoc test p: 0.01) and lower
in VD (LSD p: 0.05), while no differences were observed
as regards the CIND group (model ANOVA p < 0.001).
The distribution of 24S-OH-Chol levels (boxplots) in
Controls and patients affected by VD, LOAD or CIND
is reported in Figure 1.
In Table 2 are reported the correlations between the
24S-OH-Chol and other variables observed in the whole
sample (n. 160 subjects). Since 24S-OH-Chol and TC
plasma levels are known to be correlated [4] (in our
sample r: 0.28, p: 0.005) as they are both transported by
the low-density lipoproteins, 24S-OH-Chol values were
adjusted for TC levels by calculating the 24S-OH-Chol/
TC ratio (ng/mg). Indeed, it has been suggested that the
24S-OH-Chol/TC ratio may better reflect brain choles-
terol homeostasis than 24S-OH-Chol absolute level [4].
The 24S-OH-Chol/TC ratio was significantly corre-
lated with serum albumin (r: -020; p: 0.03), and hs.CPR
levels (r: 0.33; p: 0.001); no significant correlations
emerged with age, Barthel index, and creatinine levels.
Interestingly, the 24S-OH-Chol/TC ratio correlated
negatively with the Babcock test score (both immediate
and delayed recall), and positively with the Frontal
Assessment Battery (FAB) score. In both cases, the
higher the 24S-OH-Chol/TC ratio, the worse the perfor-
mance obtained in neuropsychological tests.
As regards TC scan findings, 24S-OH-Chol/TC ratio
was positively related to the presence of brain atrophy.
By multivariate linear regression analysis we demon-
strated that the 24S-OH-Chol/TC ratio was significantly
correlated with hs.CRP independent of age, albumin
Table 1 General characteristics and plasma levels of 24S-OH-Chol in patients with Late Onset Alzheimer’s Disease
(LOAD), Vascular Dementia (VD), Cognitive Impairment No Dementia (CIND), and in older controls.
Parameter LOAD VD CIND Controls
(n. 60) (n. 35) (n. 25) (n. 40)
Age (years)* 78 ± 5.5 77 ± 7.6 74 ± 8.2 73 ± 8.7
Female gender ^ 78,00% 53,00% 60,00% 68,00%
MMSE score (mean/SD)* 21.3 ± 3.8 21.7 ± 3.9 25 ± 3.1 28 ± 2
Barthel index § 82.5/100 79/100 96/100 96/100
GDS 5.7/15 5.3/15 6.3/15 6.2/15
Tot. Chol. (mg/dL) 210 ± 42 204 ± 32 207 ± 43 215 ± 28
Albumin (g/dL) 4.14 ± 0.38 4.11 ± 0.37 4.08 ± 0.34 4.22 ± 0.31
Hypertension 67,00% 83,00% 63,00% 67,00%
Diabetes 15,00% 34.5% 18,00% 19,00%
CHD ^ 16,00% 34.5% 12,00% 9.5%
24S-OH-Chol (ng/ml)° 51.0 (42.0-64.7) 39.1 (36.0-46.5) 47.0 (42.6-56.3) 46.3 (37.5-52.7)
Brain atrophy ^^ 84% 53% 51% 47%
Single lacune ^^ 5% 22% 7% 6.5%
Multiple lacunes ^^ 0% 55% 20% 10%
Cortical infarcts ^^ 0% 23% 11% 6%
* ANOVA (model P < 0.001) Fisher’s least significant difference (LSD) post-hoc test: C vs LOAD p < 0.01; C vs VD p < 0.05; VD vs LOAD and CIND p < 0.005
§ ANOVA (model P < 0.001) LSD p < 0.05 C and CIND vs LOAD and VD
^Chi square test p < 0.05; ^^Chi square test p < 0.001
° ANOVA (model P < 0.001) LSD p < 0.01 LOAD vs C; p < 0.05 VD vs C and CIND; p < 0.01 for LOAD vs VD
MMSE: mini mental state examination; GDS: geriatric depression scale; CHD: coronary heart disease. For 24S-OH-Chol: median (interquartile range)
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levels, brain atrophy, Babcock test, and FAB score
(ANOVA: p:0.04; r2: 0.104).
In Table 3 are reported the results of PPARgamma
Pro12Ala polymorphism genotyping in patients with
LOAD, VD, or CIND, and in 144 older controls. The
distribution of the two alleles was in Hardy-Weinberg
equilibrium. No differences emerged by comparing their
distribution in the four groups of subjects. Furthermore,
no differences in median/mean plasma 24S-OH-Chol
levels were found when individuals bearing the Ala allele
(heterozygous + homozygous) were compared with Pro/
Pro homozygote subjects (data not shown).
Discussion
We evaluated the plasma levels of 24S-OH-Chol in a
sample of aging patients affected by two different forms
Figure 1 24 Shydroxycholesterol plasma levels (boxplots) in older normal individuals (Controls) and in older subjects affected by
vascular dementia (VD), late onset Alzheimer’s disease (LOAD) or cognitive impairment-no dementia (CIND). The dashed line represents
the median value of plasma 24Shydroxycholesterol in controls (46.3 ng/ml).
Table 2 Pearson’s correlations between the 24S-OH-Chol/




Barthel index -0.06 0.70
Serum Albumin -0.20 0.03
Serum Creatinine 0.04 0.96
Hs.CRP 0.33 0.001
MMSE -0.07 0.69
Rey test (short) -0.14 0.17
Rey test (long) -0.15 0.14
Token test -0.06 0.71
Verbal fluency (letter) -0.02 0.79
Verbal fluency (category) -0.11 0.27
Babcock (immediate) -0.29 0.01
Babcock (delayed) -0.22 0.03
FAB 0.26 0.04
Trail making A 0.18 0.31
Trail making B 0.03 0.89
CT SCAN IMAGING
- Atrophy 0.17 0.05
- Cortical infarction -0.04 0.70
- Single lacune 0.01 0.84
- Multiple lacunes -0.16 0.06
MMSE: mini mental state examination; FAB: frontal assessment battery
Table 3 PPARgamma Pro12Ala polymorphism in older
patients with LOAD, VD, CIND, and in older controls.
LOAD VD CIND Controls
(n. 60) (n. 35) (n. 25) (n. 144)
Pro allele 0.92 0.91 0.89 0.92
Ala allele 0.08 0.09 0.11 0.08
Homo Pro/Pro 48 29 19 126
Etero Pro/Ala 10 6 6 16
Homo Ala/Ala 2 0 0 2
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of dementia, LOAD and VD, and in individuals with
CIND. The first interesting data emerging from our
study is the finding of higher circulating levels of 24S-
OH-Chol in patients with LOAD compared with Con-
trols. Our results seem to confirm the unique observa-
tion by Lutjohann et al. [12], while are in contrast with
following studies reporting decreased levels of 24S-OH-
Chol in LOAD patients [13-15]. Unlike that study [12],
we were not able to demonstrate in LOAD patients a
significant correlation between 24S-OH-Chol levels and
the global cognitive function (MMSE) or functional
impairment (Barthel index), perhaps because our sub-
jects were not in the very-early stage of the disease
(Global Deterioration Scale: stage 3 to 5). Our data sup-
port the hypothesis of a trend toward higher levels of
plasma 24S-OH-Chol in the early stages of LOAD,
when the rate of neurodegeneration is higher than nor-
mal, but the amount of cell loss and resulting brain
atrophy is still small. The precise mechanisms leading to
increased plasma 24S-OH-Chol levels in the early stages
of LOAD are not known. It is possible that, in these
specific conditions, cholesterol turnover might be
increased in CNS (due to neuronal degradation) and/or
that the rate of conversion of brain cholesterol to 24S-
OH-Chol might be higher compared to normal.
Interestingly, it has been observed by Brown et al. that
24S-OH-Chol is an efficient inhibitor of beta-amyloid
formation in vitro [23]; if this is true also under in vivo
conditions, the increase of 24S-OH-Chol levels in CNS
(and consequently in the circulation) might be consid-
ered as an early attempt to counteract beta-amyloid
deposition. On the contrary, in the advanced stages of
the disease low levels of 24S-OH-Chol in CNS (and
consequently in the circulation), would even accelerate
beta-amyloid deposition and the progression of LOAD.
In part, increased 24S-OH-Chol levels might also
result from a defect in blood-brain barrier, which seems
to be a frequent finding in different neurological dis-
eases including LOAD [24].
Unlike the study of Lutjohann et al. [12], but in agree-
ment with other following clinical observations [13-15],
we found that plasma 24S-OH-Chol levels were lower in
VD patients compared with controls. The difference we
observed between LOAD and VD is somehow unex-
pected, and might be related to different mechanisms.
In particular, it has to be underlined that, on average,
our VD patients were in a more advanced stage of the
disease (GDS: stage 4-6) compared with LOAD (GDS:
stage 3-5). Actually, not only it has been reported that a
decrease in plasma levels of 24S-OH-Chol would be
typical of dementia [25,8], but it has been also shown
that plasma 24S-OH-Chol levels progressively decrease
with the worsening of the disease [4]. Thus, the differ-
ences between LOAD and VD might be secondary to a
different stage of disease. Alternatively, the differences
in levels of 24S-OH-Chol between LOAD and VD might
reflect the different pathogenetic mechanisms and/or
evolution of these two forms of dementia.
We also evaluated the possible relationship between
24S-OH-Chol and other available variables. Interestingly,
by multivariate regression analysis we found that the
24S-OH-Chol/TC ratio independently correlated with
hs.CRP levels, and this explained about 10% of its total
variability. Hs.CRP is a sensitive marker of systemic
inflammation. The association between the 24S-OH-
Chol and inflammation has been already reported in
vitro [26]; indeed, Alexandrov found that in primary co-
culture of human neurons and glia, 24S-OH-Chol is
able to induce the expression of several pro-inflamma-
tory genes. The presence of a low-grade systemic
inflammation has been reported both in LOAD and VD
by several Authors, including our group [20]. The find-
ing of a significant association between 24S-OH-Chol
and CRP levels suggest a possible link between the
degree of neurodegeneration (plasma 24S-OH-Chol
would be a marker of it) and the degree of peripheral
systemic inflammation. As a matter of fact, the relation-
ship between 24S-OH-Chol/TC and CRP was strong in
LOAD (r: 0.39), was still present in CIND (r: 0.20), but
it was pratically absent in VD patients (r: 0.08). The spe-
cificity of the relationship between LOAD and increased
24S-OH-Chol plasma concentrations might be indirectly
supported by the result of univariate analysis (Table 2)
showing a significant correlation of 24S-OH-Chol with
memory tests impairment and brain atrophy on CT
scan, both typical characteristics of LOAD but not of
VD.
Finally, we evaluated the possible effect of the PPAR-
gamma Pro12Ala polymorphism on the risk of being
affected by dementia or CIND, as well as on 24S-OH-
Chol plasma levels. Infact, it has been consistently
reported that PPARgamma plays an important role in
glucose and lipid metabolism [27], which in turn have
been associated with LOAD [28,29]. We found no asso-
ciation between the PPARgamma polymorphism and
LOAD, VD or CIND. Furthermore, unlike Sauder [17]
we didn’t find any increase in 24S-OH-Chol/TC ratio
among the carriers of the Ala allele both in the whole
sample and in the three groups of patients.
The principal limitations of the study must be also
acknowledged. First, brain morphology was evaluated by
qualitative CT scan assessment and not by quantitative
MRI analysis, which is the best validated method and
would give important information. Second, CSF biomar-
kers were not available for LOAD, VD and CIND
patients enrolled into this study, and this might signifi-
cantly influence sensibility and specificity of our diag-
noses. Third, we did not systematically evaluated Apo E
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polymorphism in our sample, and it is probable that apo
E phenotype might influence plasma levels of 24S-OH-
Chol. Nevertheless, we evaluated apo E genotype in
DNA from 70% of patients (84/120); we found no differ-
ences in mean/median 24S-OH-Chol levels by compar-
ing patients bearing or not the ε4 allele (ANOVA -
Mann-Whitney test p: 0.86 and 0.96, respectively).
Fourth, although we investigated plasma 24S-OH-Chol
concentrations in a much larger sample of subjects com-
pared with previous studies, sample size might be small
when investigating the possible effect of genetics. For
this reason our negative data on PPARgamma poly-
morphism need to be replicated in larger groups of
individuals.
Conclusions
In conclusion, the results of the present study suggest
that 24S-OH-Chol plasma levels might be increased in
the first stages of LOAD, and may be correlated with
systemic inflammation.
The finding of lower 24S-OH-Chol concentrations in
VD might be related with a more advanced stage of VD
compared with LOAD in our sample, and/or to different
pathogenetic mechanisms and evolution of these two
forms of dementia.
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